Overview This page contains the latest trade data of Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937. In 2023, Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 were the world's 2903rd most traded product, with a total trade of $525M. Between 2022 and 2023 the exports of Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 decreased by -40.2%, from $878M to $525M. Trade in Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 represent 0.0023% of total world trade.
Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 are a part of Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis; derivatives and....
Exports In 2023 the top exporters of Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 were France ($133M), China ($98.2M), Ireland ($83.4M), Germany ($66.1M), and India ($43.3M).
Imports In 2023 the top importers of Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 were United States ($181M), France ($87.2M), India ($59.4M), Russia ($29.3M), and China ($27.5M).
Ranking Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in heading 2937 ranks 771st in the Product Complexity Index (PCI).